A targeted radioactive treatment for neuroendocrine tumours
Lutetium (177Lu) oxodotreotide
A targeted radioactive medicine given by drip to treat certain neuroendocrine tumours.
What is Lutetium (177Lu) oxodotreotide?
Lutetium (177Lu) oxodotreotide is a specialist radioactive medicine, a type of targeted radionuclide therapy, used to treat certain neuroendocrine tumours (slow-growing tumours that can arise in the gut and elsewhere). It works by carrying radiation directly to the tumour cells, which have a marker the medicine locks onto. It is given as a drip in a nuclear-medicine centre. Because it is radioactive, radiation-safety precautions are needed, including limiting close contact for a while. It can lower blood cells and affect the kidneys, so a protective amino-acid drip is given and monitoring is close.
Education and reference only. This is a plain-language guide to Lutetium (177Lu) oxodotreotide — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Lutetium (177Lu) oxodotreotide is a specialist radioactive medicine, a form of targeted radionuclide therapy, used to treat certain neuroendocrine tumours, which are slow-growing tumours that can develop in the gut, pancreas and other places. It combines a substance that homes in on a marker found on these tumour cells with a radioactive part that delivers radiation right where it is needed. It is given as a drip into a vein in a nuclear-medicine centre, as a course of treatments, under the care of a specialist team trained in handling radioactive medicines.
How it works
Many neuroendocrine tumour cells carry a marker (a receptor) on their surface that this medicine is designed to lock onto. Once attached, the radioactive part delivers a focused dose of radiation directly to those cells, damaging them while sparing more of the surrounding healthy tissue than treatments spread across the whole body. The radioactivity fades over time as the body clears the medicine. Because the treatment is targeted to cells with the right marker, it is used for tumours shown to carry that marker, and it is given as a planned course rather than a single dose.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist radioactive medicine given by drip in nuclear-medicine centres in the UK to treat certain neuroendocrine tumours.
Practical use
How to take Lutetium (177Lu) oxodotreotide
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a drip into a vein in a nuclear-medicine centre, as a planned course of treatments.
- A protective amino-acid drip is given alongside it to help shield your kidneys.
- Follow the radiation-safety advice exactly, including limiting close contact with others for the advised period.
- Attend all blood tests and scans between treatments, as blood counts and kidneys are monitored.
- Tell the team if you feel unwell, develop signs of infection, or have unusual bruising or bleeding.
Weighing it up
Advantages & disadvantages of Lutetium (177Lu) oxodotreotide
Advantages
- Delivers radiation directly to neuroendocrine tumour cells that carry the right marker, sparing more healthy tissue.
- A targeted option for tumours that may not respond well to other treatments.
- Given as a planned course under expert specialist care.
Disadvantages
- Requires radiation-safety precautions, including limiting close contact with others for a time.
- Can lower blood cells and can affect the kidneys, needing protection and monitoring.
- Only available in specialist nuclear-medicine centres as part of a course.
Practical use
Good to know
This is a radioactive, targeted treatment given in a nuclear-medicine centre, so several special precautions apply. Because you become mildly radioactive for a time afterwards, you will be given radiation-safety advice, such as limiting close and prolonged contact with others, especially children and pregnant women, and careful use of the toilet, for a period after each treatment. It can lower blood cells (affecting infection-fighting, clotting and energy), so blood counts are checked between treatments. It can also affect the kidneys, so a protective amino-acid drip is given alongside it to help shield them, and kidney function is monitored. Nausea and tiredness are common around treatment. The specialist team plans the course, gives anti-sickness support, and tells you exactly which precautions to follow and for how long.
Who should not take it / use with caution
- It must not be used in pregnancy because radiation can harm an unborn baby; effective contraception is needed.
- It is used with care, or avoided, in people with significant kidney problems or very low blood counts.
- It should only be given by a specialist team in a nuclear-medicine centre, with full precautions.
Monitoring
- Blood counts checked between treatments to watch for low blood cells.
- Kidney function monitored, with a protective amino-acid drip given during treatment.
- Scans and reviews to see how the tumour is responding over the course.
Side effects
- Nausea, vomiting or tiredness around the time of treatment.
- Lowered blood cells, increasing the risk of infection, bruising, bleeding or tiredness.
- Effects on the kidneys, and, rarely, longer-term effects on the bone marrow.
Key interactions
- Certain hormone medicines used for neuroendocrine tumours may need timing adjusted around treatment.
- Tell the team about all your medicines, including any that affect the kidneys or blood counts.
- Other treatments affecting the bone marrow are reviewed carefully alongside it.
Available as: A radioactive solution given as a drip into a vein in a nuclear-medicine centre.
Answers
Lutetium (177Lu) oxodotreotide: frequently asked questions
What is this medicine used for?
It is a targeted radioactive treatment used for certain neuroendocrine tumours, carrying radiation directly to tumour cells that have a marker it locks onto.
Why do I need radiation-safety precautions?
You become mildly radioactive for a time afterwards, so you are advised to limit close contact with others, especially children and pregnant women, for a period.
Why is an amino-acid drip given with it?
The treatment can affect the kidneys, so a protective amino-acid drip is given alongside to help shield them, and kidney function is monitored.
Will it affect my blood?
It can lower blood cells, which can increase the risk of infection, bruising or tiredness, so your blood counts are checked between treatments.
Where is it given?
It is given as a drip in a specialist nuclear-medicine centre, as a planned course, by a team trained in handling radioactive medicines.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.